Media stories about Insulet (NASDAQ:PODD) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Insulet earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the medical instruments supplier an impact score of 44.372133370518 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Shares of Insulet opened at $93.79 on Friday, Marketbeat Ratings reports. Insulet has a 52-week low of $40.92 and a 52-week high of $96.38. The firm has a market capitalization of $5.53 billion, a P/E ratio of -203.89 and a beta of 1.39. The company has a quick ratio of 5.16, a current ratio of 5.48 and a debt-to-equity ratio of 3.34.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, May 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.08. Insulet had a negative net margin of 4.82% and a negative return on equity of 20.02%. The company had revenue of $123.60 million during the quarter, compared to analyst estimates of $121.76 million. During the same period in the previous year, the business earned ($0.17) earnings per share. The firm’s quarterly revenue was up 21.5% compared to the same quarter last year. sell-side analysts predict that Insulet will post -0.2 EPS for the current year.

Several research analysts have recently weighed in on the stock. Canaccord Genuity upped their price target on shares of Insulet from $96.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, May 23rd. Berenberg Bank assumed coverage on shares of Insulet in a report on Friday, April 20th. They issued a “buy” rating and a $100.00 price target on the stock. Piper Jaffray Companies upped their price target on shares of Insulet from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, May 3rd. Oppenheimer set a $90.00 price target on shares of Insulet and gave the stock a “hold” rating in a report on Friday, May 4th. Finally, ValuEngine raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Insulet has a consensus rating of “Buy” and a consensus price target of $88.71.

In other Insulet news, Director David A. Lemoine sold 641 shares of the company’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $49,235.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Shacey Petrovic sold 1,319 shares of the company’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $101,312.39. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,514 shares of company stock valued at $5,437,259. Company insiders own 3.60% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.